WRBC
EUCRW

W.R. Berkley Corp’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

W.R. Berkley Corp’s Portfolio EUCRW Stock Details EUCRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-26,383
Closed -$5K – 572
2022
Q1 		$5K Buy
+26,383
New +$10.7K ﹤0.01% 573

Other funds holding EUCRW

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
AI
Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

W.R. Berkley Corp's EUCRW Position: Q2 2022 in Review

W.R. Berkley Corp sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q2 2022, closing a stake of 26,383 shares — an estimated $5K sold.

W.R. Berkley Corp first reported a position in EUCRW in Q1 2022 and held it in 1 quarter. The position peaked at $5K in Q1 2022. 26 funds tracked by Wall St. Rank hold EUCRW as of Q2 2022.

  • W.R. Berkley Corp reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q2 2022 after selling out during the quarter.
  • W.R. Berkley Corp sold 26,383 Eucrates Biomedical Acquisition Corp. Warrant shares in Q2 2022, an estimated $5K.
  • W.R. Berkley Corp first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q1 2022 and held it in 1 quarter.
  • W.R. Berkley Corp's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $5K in Q1 2022.
  • 26 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q2 2022.

Based on W.R. Berkley Corp's 13F filing for Q2 2022, filed 15 Aug 2022.